Hi @eloise999 You posed a great question as to whether patients with ET needed to fail on HU first before they can receive Besremi. Apparently that’s not the case. After a little more digging this is what I found this morning regarding eligibility. It appears there is no requirement limit to who may receive the drug.

This quote is from Curetoday.com (link to full article below)
“The approval, announced by PharmaEssentia USA Corporation, makes BESREMi the first new FDA-approved treatment for essential thrombocythemia in nearly 30 years. >The approval applies to adults with ET regardless of their genetic profile or disease status, including people who have been newly diagnosed and have not previously received cytoreductive therapy.”

From Curetoday.com:
https://www.curetoday.com/view/fda-approves-besremi-for-essential-thrombocythemia-expanding-treatment-options
A few more links with information on Besremi’s approval Aug 31, 2026.
FDA;
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia
~~~~
From Besremi.com
https://besremi.com/et/
This drug has the potential to change course of the disease by reducing the JAK2 mutated cells. But it may not be for everyone and will take consideration from both patients and doctors to make the right decision on treatment plans. It’s certainly encouraging though.